Abstract
We appreciate the letter from Shapiro et al. The authors highlighted insightful questions regarding the patient population treated in our study [ [1] Yip W, Ghoreifi A, Gerald T, et al. Perioperative complications and oncologic outcomes of nephrectomy following immune checkpoint inhibitor therapy: a multicenter collaborative study. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2023.03.003. Google Scholar ] to improve the interpretation and generalizability of such data, which we feel is an important addition to the literature, alongside their recent report on 75 patients who similarly underwent cytoreductive nephrectomy following immune checkpoint inhibitor (ICI) therapy [ [2] Shapiro D.D. Karam J.A. Zemp L. et al. Cytoreductive nephrectomy following immune checkpoint inhibitor therapy is safe and facilitates treatment-free intervals. Eur Urol Open Sci. 2023; 50: 43-46 Abstract Full Text Full Text PDF PubMed Scopus (0) Google Scholar ].
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
